Monoclonal Antibody Therapy for B-Cell Lymphoma: Clinical Trials of an Anti-CD20 Monoclonal Antibody for B-Cell Lymphoma in Japan

2002 ◽  
Vol 76 (5) ◽  
pp. 411-419 ◽  
Author(s):  
Kensei Tobinai
Keyword(s):  
Monoclonal Antibody ◽  
Clinical Trials ◽  
B Cell ◽  
Cell Lymphoma ◽  
Antibody Therapy ◽  
B Cell Lymphoma ◽  
Monoclonal Antibody Therapy ◽  
Anti Cd20

148 90Y-anti-CD20 monoclonal antibody therapy for recurrent B cell lymphoma

1995 ◽  
Vol 32 ◽  
pp. 215 ◽  
Author(s):  
Susan J. Knox ◽  
Michael L. Goris ◽  
Kirk D. Trisler ◽  
Tom A. Davis ◽  
Tina-Marie Liles ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
B Cell ◽  
Cell Lymphoma ◽  
Antibody Therapy ◽  
B Cell Lymphoma ◽  
Monoclonal Antibody Therapy ◽  
Anti Cd20

90Y-ANTI-CD20 MONOCLONAL ANTIBODY THERAPY (IDEC-Y2B8) FOR RECURRENT B CELL LYMPHOMA

1994 ◽  
Vol 16 (2) ◽  
pp. 161 ◽  
Author(s):  
S. J. Knox ◽  
M. Goris ◽  
M. Becker ◽  
S. Fowler ◽  
K. Trisler ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
B Cell ◽  
Cell Lymphoma ◽  
Antibody Therapy ◽  
B Cell Lymphoma ◽  
Monoclonal Antibody Therapy ◽  
Anti Cd20

scholarly journals Macrophage-Mediated Antibody Dependent Effector Function in Aggressive B-Cell Lymphoma Treatment is Enhanced by Ibrutinib via Inhibition of JAK2

Cancers ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 2303
Author(s):  
Verena Barbarino ◽  
Sinika Henschke ◽  
Stuart Blakemore ◽  
Elena Izquierdo ◽  
Michael Michalik ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
B Cell ◽  
Cell Lymphoma ◽  
Antibody Therapy ◽  
B Cell Lymphoma ◽  
Lymphocytic Leukemia ◽  
Janus Kinase ◽  
Monoclonal Antibody Therapy ◽  
Antibody Treatment ◽  
Btk Inhibitors

Targeted inhibition of Bruton’s Tyrosine Kinase (BTK) with ibrutinib and other agents has become important treatment options in chronic lymphocytic leukemia, Waldenström’s Macroglobulinemia, Mantle cell lymphoma, and non-GCB DLBCL. Clinical trials combining small molecule inhibitors with monoclonal antibodies have been initiated at rapid pace, with the biological understanding between their synergistic interactions lagging behind. Here, we have evaluated the synergy between BTK inhibitors and monoclonal antibody therapy via macrophage mediated antibody dependent cellular phagocytosis (ADCP). Initially, we observed increased ADCP with ibrutinib, whilst second generation BTK inhibitors failed to synergistically interact with monoclonal antibody treatment. Kinase activity profiling under BTK inhibition identified significant loss of Janus Kinase 2 (JAK2) only under ibrutinib treatment. We validated this potential off-target effect via JAK inhibition in vitro as well as with CRISPR/Cas9 JAK2−/− experiments in vivo, showing increased ADCP and prolonged survival, respectively. This data supports inhibition of the JAK-STAT (Signal Transducers and Activators of Transcription) signaling pathway in B-cell malignancies in combination with monoclonal antibody therapy to increase macrophage-mediated immune responses.

scholarly journals Macrophage-mediated antibody dependent effector function in aggressive B-cell lymphoma treatment is enhanced by Ibrutinib via inhibition of JAK2

2020 ◽  
Author(s):  
Verena Barbarino ◽  
Sinika Henschke ◽  
Stuart James Blakemore ◽  
Elena Izquierdo ◽  
Michael Michalik ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
B Cell ◽  
Cell Lymphoma ◽  
Antibody Therapy ◽  
B Cell Lymphoma ◽  
Lymphocytic Leukemia ◽  
Janus Kinase ◽  
Monoclonal Antibody Therapy ◽  
Antibody Treatment ◽  
Btk Inhibitors

AbstractTargeted inhibition of Bruton’s Tyrosine Kinase (BTK) with ibrutinib and other agents has become important treatment options in chronic lymphocytic leukemia, Waldenström’s Macroglobulinemia, Mantle cell lymphoma and non-GCB DLBCL. Clinical trials combining small molecule inhibitors with monoclonal antibodies have been initiated at rapid pace, with the biological understanding between their synergistic interactions lagging behind. Here, we have evaluated the synergy between BTK inhibitors and monoclonal antibody therapy via macrophage mediated antibody dependent cellular phagocytosis (ADCP). Initially, we observed increased ADCP with ibrutinib, whilst second generation BTK inhibitors failed to synergistically interact with monoclonal antibody treatment. Kinase activity profiling under BTK inhibition identified significant loss of Janus Kinase 2 (JAK2) only under ibrutinib treatment. We validated this potential off-target effect via JAK inhibition in vitro as well as with CRISPR/Cas9 JAK2−/− experiments in vivo, showing increased ADCP and prolonged survival, respectively. This data supports inhibition of the JAK-STAT signaling pathway in B-cell malignancies in combination with monoclonal antibody therapy to increase macrophage mediated immune responses.

Sign in / Sign up

Export Citation Format

Share Document